



**DIRECTOR DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013**

January 27, 2021

BRIDGEWATER, N.J., Jan. 27, 2021 (GLOBE NEWSWIRE) --

fAp9

**APPENDIX 3  
DISCLOSURE FORMS**

**FORM 8.1(a)&(b)(i)**

**IRISH TAKEOVER PANEL**

**DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013**

**DEALINGS BY OFFERORS, OFFEREEES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS**

**1. KEY INFORMATION**

<b>Name of person dealing</b> (Note 1)	Gregory L. Cowan
<b>Company dealt in</b>	Osmotica Pharmaceuticals plc
<b>Class of relevant security to which the dealings being disclosed relate</b> (Note 2)	Ordinary Shares of US\$0.01 each ( <b>Ordinary Shares</b> )
<b>Date of dealing</b>	January 27, 2021

**2. INTERESTS AND SHORT POSITIONS**

**(a) Interests and short positions (following dealing) in the class of relevant security dealt in** (Note 3)

	<b>Long</b>		<b>Short</b>	
	<b>Number</b>	<b>(%)</b>	<b>Number</b>	<b>(%)</b>
<b>(1) Relevant securities</b>	Ordinary Shares: 31,183 (0.05%)		N/A	
<b>(2) Derivatives (other than options)</b>	N/A		N/A	
<b>(3) Options and agreements to purchase/sell</b>	Restricted stock units ( <b>RSUs</b> ) pursuant to the Osmotica Pharmaceuticals plc 2018 Incentive Plan (the <b>Plan</b> ): 50,185 (0.08%)		N/A	
<b>Total</b>	81,368 (0.13%)		N/A	

**(b) Interests and short positions in relevant securities of the company, other than the class dealt in** (Note 3)

<b>Class of relevant security:</b>	<b>Long</b>		<b>Short</b>	
	<b>Number</b>	<b>(%)</b>	<b>Number</b>	<b>(%)</b>
<b>(1) Relevant securities</b>	N/A		N/A	
<b>(2) Derivatives (other than options)</b>	N/A		N/A	
<b>(3) Options and agreements to purchase/sell</b>	N/A		N/A	
<b>Total</b>	N/A		N/A	

Ap10

**3. DEALINGS** (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
N/A	N/A	N/A

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)
N/A	N/A	N/A	N/A

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)
N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)
N/A	N/A	N/A

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)
Vesting of RSUs pursuant to the Plan	5,962 ordinary shares issued following the vesting of RSUs pursuant to the Plan	N/A

Ap11

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
N/A

Is a Supplemental Form 8 attached? (Note 9)

NO

Date of disclosure	January, 27, 2021
Contact name	Lisa M. Wilson
Telephone number	+ 1 212-452-2793
Name of offeree/offeree with which acting in concert	Osmodica Pharmaceuticals plc
Specify category and nature of acting in concert status	Director